HIV AIDS diagnostic study of choice

Jump to navigation Jump to search

Sexually transmitted diseases Main Page

AIDS Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating AIDS from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

HIV Opportunistic Infections

HIV Coinfections

HIV and Pregnancy

HIV Infection in Infants

Diagnosis

Diagnostic Study of Choice

AIDS Case Definition

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Nutrition
Drug Resistance

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

HIV Vaccine

Case Studies

Case #1

HIV AIDS diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of HIV AIDS diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on HIV AIDS diagnostic study of choice

CDC on HIV AIDS diagnostic study of choice

HIV AIDS diagnostic study of choice in the news

Blogs on HIV AIDS diagnostic study of choice

Directions to Hospitals Treating AIDS

Risk calculators and risk factors for HIV AIDS diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Diagnostic Study of Choice

Study of choice

Fourth generation test(ELISA/ELI/MEIA/ELFA/ECLIA) have high sensitivity; therefore they are used as confirmatory test. These test can detect both p24 antigen as well as HIV antibodies.

Screening Immunoassays

There have been five generations of enzyme immunoassays(EIAs) that use different [[antigen] compositions and detection chemistries to give precise and high volume samples for laboratories.[1]

  • First Generation Assay: It used antigen lysate preparations to detect antibodies; however due to high false positivity it was replaced by highly specific immunoassays and western blot techniques.
  • Second Generation Assay: Proteins derived from Immunodominant regions(IDR) of HIV-1 proteins and gp36 of HIV-2 were used to increase sensitivity and decrease false positivity.
  • Third Generation Assay: Detection of Ig G antibodies by using antigens such as gp160 derived from HIV-1 group M, recombinant p24, recombinant peptide from HIV-2 gp36 IDR and synthetic peptide from HIV-1 group O. It also detected HIV-1 IgM to further reduce window period.
  • Fourth Generation: It detected both antigen and antibodies at the same time using fully automated chemiluminescent microparticle.
  • Fifth Generation: It used multiplex format to detect distinguished p24 antigen of HIV-1 and HIV-2.

Confirmatory Immunoassays

The specimens that were reactive with EIAs need to be retested with more specific confirmatory test which is Western Blot using a gradient purified HIV lysate, electrophorese and suffused onto nitrocellulose strips. For WB to be considered positive, it has to contain antibodies reactive to p24 antigen and envelope glycoproteins.

Rapid Testing Assays

The rapid tests is completed in about 20-30 mins making it ideal in primary care and mobile clinics. Non-laboratory staff can perform these test as it require finger prick blood sample or oral fluid. Although these are less sensitive than EIAs; however, their specificity is higher.




The comparison of various diagnostic studies for [disease name]

Test Sensitivity Specificity
Test 1 ...% ...%
Test 2 ...% ...%

[Name of test with higher sensitivity and specificity] is the preferred investigation based on the sensitivity and specificity

Diagnostic results

The following finding(s) on performing [investigation name] is(are) confirmatory for [disease name]:

  • [Finding 1]
  • [Finding 2]
Sequence of Diagnostic Studies

The [name of investigation] must be performed when:

  • The patient presented with symptoms/signs 1, 2, and 3 as the first step of diagnosis.
  • A positive [test] is detected in the patient, to confirm the diagnosis.

OR

The various investigations must be performed in the following order:

  • [Initial investigation]
  • [2nd investigation]

Name of Diagnostic Criteria

It is recommended that you include the criteria in a table. Make sure you always cite the source of the content and whether the table has been adapted from another source.

[Disease name] is primarily diagnosed based on clinical presentation. There are no established criteria for the diagnosis of [disease name].

OR

There is no single diagnostic study of choice for [disease name], though [disease name] may be diagnosed based on [name of criteria] established by [...].

OR

The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].

OR

The diagnosis of [disease name] is based on the [criteria name] criteria, which includes [criterion 1], [criterion 2], and [criterion 3].

OR

[Disease name] may be diagnosed at any time if one or more of the following criteria are met:

  • Criteria 1
  • Criteria 2
  • Criteria 3

OR

IF there are clear, established diagnostic criteria

The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].

OR

The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].

OR

The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].

OR

IF there are no established diagnostic criteria

There are no established criteria for the diagnosis of [disease name].

References

  1. Parekh BS, Ou CY, Fonjungo PN, Kalou MB, Rottinghaus E, Puren A; et al. (2019). "Diagnosis of Human Immunodeficiency Virus Infection". Clin Microbiol Rev. 32 (1). doi:10.1128/CMR.00064-18. PMC 6302353. PMID 30487166.

Template:WH Template:WS